-
Rivaroxaban (Xarelto) and PE
Stephan Moll, MD writes… Good news: The large phase 3 clinical trial comparing 3-12 months treatment of Rivaroxaban (Xarelto) with warfarin in patients with newly diagnosed pulmonary embolism was published on 3-26-2012 in the New England Journal of Medicine [reference 1], showing that Rivaroxaban was (a) noninferior to warfarin in its efficacy, (b) caused the…
-
New ACCP Guidelines – DVT and PE: Highlights and Summary
Stephan Moll, MD writes… This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here
-
Xarelto and DVT – Approved in Europe
Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news
-
Aspirin – Does it Prevent DVT and PE?
To some degree it does, but it is by far not as effective as warfarin or other anticoagulants. However, a very noteworthy study was presented today
-
VTE Prevention in Hospitalized Patients: New ACP Guideline
A new guideline was published this week about venous thromboembolism (VTE) prophylaxis in hospitalized medical sick patients and in stroke patients [link here; ref 1]. The key points of this guideline,
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 